1. Home
  2. ONC vs KEYS Comparison

ONC vs KEYS Comparison

Compare ONC & KEYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • KEYS
  • Stock Information
  • Founded
  • ONC 2010
  • KEYS 1939
  • Country
  • ONC Cayman Islands
  • KEYS United States
  • Employees
  • ONC N/A
  • KEYS N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • KEYS Industrial Machinery/Components
  • Sector
  • ONC Health Care
  • KEYS Industrials
  • Exchange
  • ONC Nasdaq
  • KEYS Nasdaq
  • Market Cap
  • ONC 26.9B
  • KEYS 25.9B
  • IPO Year
  • ONC N/A
  • KEYS N/A
  • Fundamental
  • Price
  • ONC $231.99
  • KEYS $154.04
  • Analyst Decision
  • ONC Strong Buy
  • KEYS Buy
  • Analyst Count
  • ONC 7
  • KEYS 9
  • Target Price
  • ONC $326.43
  • KEYS $181.33
  • AVG Volume (30 Days)
  • ONC 471.3K
  • KEYS 909.9K
  • Earning Date
  • ONC 05-07-2025
  • KEYS 05-20-2025
  • Dividend Yield
  • ONC N/A
  • KEYS N/A
  • EPS Growth
  • ONC N/A
  • KEYS N/A
  • EPS
  • ONC N/A
  • KEYS 3.50
  • Revenue
  • ONC $4,175,868,000.00
  • KEYS $5,018,000,000.00
  • Revenue This Year
  • ONC $860.73
  • KEYS $7.43
  • Revenue Next Year
  • ONC $19.79
  • KEYS $6.23
  • P/E Ratio
  • ONC N/A
  • KEYS $43.97
  • Revenue Growth
  • ONC 51.16
  • KEYS N/A
  • 52 Week Low
  • ONC $141.31
  • KEYS $119.72
  • 52 Week High
  • ONC $287.88
  • KEYS $186.20
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • KEYS 63.42
  • Support Level
  • ONC N/A
  • KEYS $145.51
  • Resistance Level
  • ONC N/A
  • KEYS $150.27
  • Average True Range (ATR)
  • ONC 0.00
  • KEYS 3.49
  • MACD
  • ONC 0.00
  • KEYS 1.97
  • Stochastic Oscillator
  • ONC 0.00
  • KEYS 97.78

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About KEYS Keysight Technologies Inc.

Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.

Share on Social Networks: